| Tal Mednick Md Pc | |
|
350 Veterans Memorial Hwy Ste 2 Commack NY 11725-4316 | |
| (631) 309-5222 | |
| (631) 303-3380 |
| Full Name | Tal Mednick Md Pc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 350 Veterans Memorial Hwy Ste 2, Commack, New York |
| Authorized Official Name and Position | Tal Mednick (PRESIDENT) |
| Authorized Official Contact | 6313095222 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Tal Mednick Md Pc 350 Veterans Memorial Hwy Ste 2 Commack NY 11725-4316 Ph: (631) 309-5222 | Tal Mednick Md Pc 350 Veterans Memorial Hwy Ste 2 Commack NY 11725-4316 Ph: (631) 309-5222 |
| NPI Number | 1306571740 |
|---|---|
| Provider Enumeration Date | 07/20/2022 |
| Last Update Date | 04/17/2023 |
| Certification Date | 04/17/2023 |
| Medicare PECOS PAC ID | 4587048863 |
|---|---|
| Medicare Enrollment ID | O20220906001636 |
News Archive
Angiotech Pharmaceuticals, Inc. has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its innovative 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) in the United States.
A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.
Availability of safe platelets is a fundamental blood transfusion challenge and can be especially problematic in times of emergency. Several studies presented at the annual American Association of Blood Banks (AABB) meeting today demonstrate new approaches to counteract platelet shortages by enhancing the safety of whole blood derived platelets, precluding the need to rely on only those obtained through apheresis.
Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.
The structure of the chaperonin complex of the bacteria Thermus thermophilus reveals clues about how the important molecule may do its job of folding new or damaged proteins within cells.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306571740 | NPI | - | NPPES |
| 270642 | Other | NY | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | (* (Not Available)) | Primary |
| Provider Name | Tal Mednick |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1700105590 PECOS PAC ID: 8426279803 Enrollment ID: I20141028002933 |
News Archive
Angiotech Pharmaceuticals, Inc. has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its innovative 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) in the United States.
A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.
Availability of safe platelets is a fundamental blood transfusion challenge and can be especially problematic in times of emergency. Several studies presented at the annual American Association of Blood Banks (AABB) meeting today demonstrate new approaches to counteract platelet shortages by enhancing the safety of whole blood derived platelets, precluding the need to rely on only those obtained through apheresis.
Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.
The structure of the chaperonin complex of the bacteria Thermus thermophilus reveals clues about how the important molecule may do its job of folding new or damaged proteins within cells.
› Verified 6 days ago
News Archive
Angiotech Pharmaceuticals, Inc. has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its innovative 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) in the United States.
A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.
Availability of safe platelets is a fundamental blood transfusion challenge and can be especially problematic in times of emergency. Several studies presented at the annual American Association of Blood Banks (AABB) meeting today demonstrate new approaches to counteract platelet shortages by enhancing the safety of whole blood derived platelets, precluding the need to rely on only those obtained through apheresis.
Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.
The structure of the chaperonin complex of the bacteria Thermus thermophilus reveals clues about how the important molecule may do its job of folding new or damaged proteins within cells.
› Verified 6 days ago
Turning Points Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 283 Commack Rd Ste 210, Commack, NY 11725 Phone: 631-858-1090 Fax: 631-499-0534 | |
United Supports For Autism Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 283 Commack Rd., Suite 205, Commack, NY 11725 Phone: 516-848-8551 | |
Karen Ness Lcsw Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 340 Veterans Memorial Hwy Ste 8, Commack, NY 11725 Phone: 631-988-7229 Fax: 631-698-7151 | |
David L. Kreitzman, M.d., P.c. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 283 Commack Rd, Suite 101, Commack, NY 11725 Phone: 631-462-7774 | |
Mateer Orthodontics Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 66 Commack Rd Ste 102, Commack, NY 11725 Phone: 631-462-1970 | |
Janis Hoffman Lcsw ,pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2171 Jericho Tpke Ste 335, Commack, NY 11725 Phone: 917-596-1040 | |
Ashley Patrick Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 417 Townline Rd, Commack, NY 11725 Phone: 631-827-9189 |